Abstract: The present invention relates to compounds of the formula (I), to the use of compounds of the formula (I) in electronic devices and electronic devices comprising one or more compounds of the formula (I). The invention furthermore relates to the preparation of the compounds of the formula (I) and to formulations comprising one or more compounds of the formula (I).
Type:
Grant
Filed:
December 21, 2016
Date of Patent:
August 18, 2020
Assignee:
Merck Patent GmbH
Inventors:
Irina Martynova, Adam W. Franz, Christof Pflumm, Amir H. Parham, Arne Buesing, Remi M. Anemian, Anja Gerhard
Abstract: Molybdenum complexes and use thereof in thin film deposition, such as CVD and ALD are provided herein. The molybdenum complexes correspond in structure to Formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are independently selected from the group consisting of hydrogen, alkyl, and trialkylsilyl; and at least one of R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 is trialkylsilyl.
Abstract: The invention relates to a reactive mesogen (RM) formulation comprising a conductive additive, to a polymer film obtained thereof, and the use of the RM formulation and polymer film in optical or electrooptical components or devices, like optical retardation films for liquid crystal displays (LCDs).
Type:
Grant
Filed:
June 22, 2017
Date of Patent:
August 18, 2020
Assignee:
Merck Patent GmbH
Inventors:
Graham Smith, Owain Llyr Parri, Vicki Cook, Georg Bernatz, David Wilkes, Jonathan Henry Wilson, Mark James, Philip Edward May
Abstract: A process for solubilization and refolding of precursor insulin or insulin analogs from inclusion body isolates for use in the production of insulin or insulin analog is described.
Type:
Grant
Filed:
August 29, 2016
Date of Patent:
August 18, 2020
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Allison D. Ortigosa, Rebecca A. Chmielowski, Mark C. Sleevi
Abstract: The present invention relates to alkaline earth aluminate phosphors, to a process for the preparation thereof and to the use thereof as conversion phosphors. The present invention also relates to an emission-converting material comprising at least the conversion phosphor according to the invention, and to the use thereof in light sources, in particular pc-LEDs (phosphor converted light emitting devices). The present invention furthermore relates to light sources, in particular pc-LEDs, and to lighting units which comprise a primary light source and the emission-converting material according to the invention.
Type:
Grant
Filed:
March 2, 2016
Date of Patent:
August 18, 2020
Assignee:
MERCK PATENT GMBH
Inventors:
Aleksander Zych, Mathias Rapphahn, Ralf Petry, Ingo Koehler, Andreas Benker, Stefan Tews
Abstract: The present invention relates to piperidine or piperazine linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug. The compounds of the invention are useful in human and veterinary medicine for inhibiting CYP3A4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by CYP3A4.
Type:
Grant
Filed:
November 7, 2014
Date of Patent:
August 18, 2020
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Craig A. Coburn, Milana M. Maletic, Yunfu Luo, Zhiqi Qi, Tingting Yu, Richard Soll
Abstract: The invention provides certain bicylic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2, R3, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
Inventors:
Thomas D. Aicher, Chad A. VanHuis, William D. Thomas, John K. MacLean, Brian M. Andresen, Kenneth J. Barr, Corey E. Bienstock, Neville J. Anthony, Matthew Daniels, Kun Liu, Yuan Liu, Catherine M. White, Blair T. Lapointe, Nunzio Sciammetta, Vladimir Simov
Abstract: A compound of formula (IV) or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer thereof These imidazolonylquinoline compounds are useful in the inhibition, regulation and/or modulation of signal transduction by kinases, in particular ATM kinase, furthermore in pharmaceutical compositions, and in their use for the treatment of diseases which relate to ATM kinase, in particular cancer.
Abstract: Compounds of Formula I and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
Abstract: A light modulation element comprising, preferably consisting of a cholesteric liquid crystalline medium sandwiched between two opposing substrates, an electrode arrangement, which is capable to allow the application of an electric field, which is substantially perpendicular to the main plane of substrate or the layer of the cholesteric liquid-crystalline medium, characterized in that one of the substrates is provided with a processed alignment layer adjacent to the cholesteric liquid crystalline medium and the other substrate is either provided with an unprocessed alignment layer adjacent to the cholesteric liquid crystalline medium or is not provided with an alignment layer. The invention is further related to a method of production of said light modulation element and to the use of said light modulation element in various types of optical and electro-optical devices, such as electro-optical displays, liquid crystal displays (LCDs), non-linear optic (NLO) devices, and optical information storage devices.
Type:
Application
Filed:
May 16, 2017
Publication date:
August 13, 2020
Applicant:
Merck Patent GmbH
Inventors:
Bernd FIEBRANZ, Peter BEST, Meike KRUMWIEDE, Simon SIEMIANOWSKI
Abstract: The invention relates to a liquid crystal mixture characterised in that it comprises one or more photoreactive mesogens of formula I wherein the parameters and groups occurring are defined as indicated in claim 1, to a process for the fabrication of liquid crystal displays using these liquid crystal mixtures and to a liquid crystal display obtainable by this process. The invention further relates to new compounds of formula I.
Type:
Application
Filed:
December 2, 2016
Publication date:
August 13, 2020
Applicant:
MERCK PATENT GMBH
Inventors:
Kevin ADLEM, Alex DAVIS, Joseph SARGENT, Ian Charles SAGE, Edward PLUMMER, Izumi SAITO, Rocco FORTTE, Helga HAAS, Lars LIETZAU
Abstract: The present application relates to a liquid-crystalline material comprising a sterically hindered N-oxide and a dye. The invention furthermore relates to the use of the liquid-crystalline material in an optical switching device for regulation of the passage of sunlight.
Type:
Application
Filed:
May 16, 2017
Publication date:
August 13, 2020
Applicant:
MERCK PATENT GMBH
Inventors:
Michael JUNGE, Ursula PATWAL, Ewa Dominica PTAK
Abstract: Compounds of the formula I in which X, Q, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.
Abstract: The present invention relates to liquid-crystalline media comprising one or more pleochroic compounds, and one or more compounds selected from the group of compounds of formulae I, II and III, in which the groups have the meanings as set forth in claim 1, and to components comprising these media for high-frequency technology, in particular phase shifters and microwave array antennas.
Type:
Application
Filed:
January 20, 2017
Publication date:
August 13, 2020
Applicant:
Merck Patent GmbH
Inventors:
Michael WITTEK, Dagmar KLASS, Peer KIRSCH
Abstract: The present invention relates to the use of spray-dried sorbitol, such as ParteckĀ® SI, as plasticizer for polymer containing compositions processed by (hot) melt extrusion. Due to its improved properties, achieved by its special manufacturing process (spray drying), this direct compressible excipient shows more additional benefits than the same substance in crystalline state.
Type:
Application
Filed:
May 10, 2017
Publication date:
August 13, 2020
Applicant:
MERCK PATENT GMBH
Inventors:
Dieter LUBDA, Mengyao ZHENG, Alessandro Giuseppe ELIA, Nicole DI GALLO
Abstract: The present invention relates to the use of sulfocysteine and derivatives thereof as cell culture additives to reduce the trisulfide levels in proteins produced in cell culture.
Abstract: The present invention is directed to 5-alkyl pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
Type:
Application
Filed:
February 11, 2020
Publication date:
August 13, 2020
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
Stephane L. BOGEN, Dane James CLAUSEN, Deodial Guy GUIADEEN, Michael T. RUDD, Dexi YANG
Abstract: The invention relates to a polymerisable LC material comprising at least one di- or multireactive mesogenic compound and at least one compound of formula CO-1, wherein L31, L32, A31, and R31 have one of the meanings as given in claim 1. Furthermore, the present invention relates also to a method for its preparation, a polymer film with improved thermal durability obtainable from the corresponding polymerisable LC material, to a method of preparation of such polymer film, and to the use of such polymer film and said polymerisable LC material for optical, electro-optical, decorative or security devices.
Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
Abstract: The present invention relates to dielectrically positive liquid-crystalline media comprising one or more compounds of the formula I, and one or more compounds selected from the group of the compounds of the formulae II and III and/or IV, in which the parameters have the respective meanings indicated in the specification, and optionally one or more further dielectrically positive compounds and optionally one or more further dielectrically neutral compounds, and to liquid-crystal displays, especially active-matrix displays and in particular TN, IPS and FFS displays, containing these media.
Type:
Grant
Filed:
July 5, 2016
Date of Patent:
August 11, 2020
Assignee:
MERCK PATENT GMBH
Inventors:
Michael Junge, Volker Reiffenrath, Elvira Montenegro, Michael Wittek, Markus Czanta